Advertisement
Australia markets closed
  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     
  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     
  • AUD/USD

    0.6546
    +0.0023 (+0.36%)
     
  • OIL

    83.63
    +0.06 (+0.07%)
     
  • GOLD

    2,358.50
    +16.00 (+0.68%)
     
  • Bitcoin AUD

    98,421.62
    +656.35 (+0.67%)
     
  • CMC Crypto 200

    1,388.44
    -8.09 (-0.58%)
     
  • AUD/EUR

    0.6093
    +0.0020 (+0.33%)
     
  • AUD/NZD

    1.0982
    +0.0024 (+0.22%)
     
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     
  • FTSE

    8,107.10
    +28.24 (+0.35%)
     
  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     
  • DAX

    18,051.39
    +134.11 (+0.75%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

Lyft Added to Tactical Underperform List at Evercore ISI

By Sam Boughedda

Investing.com — Evercore ISI analyst Mark Mahaney told investors in a research note that he has added Lyft Inc (NASDAQ:LYFT) to the firm's Tactical Asset Positioning (TAP) Underperformance List.

Mahaney, who kept an outperform rating and $75 price target on the stock, said he is adding Lyft to the list with a short-term horizon.

Lyft shares are down 4.5% Wednesday.

The analyst acknowledged that the rising number of Covid-19 cases arising from the Omicron variant weigh on any potential upside to revenue estimates for the fourth quarter.

“We are taking a short-term outlook on LYFT, as we view Omicron to pose headwinds to Q4/Q1 Revenue," said the Evercore analyst.

ADVERTISEMENT

However, he noted that "the main risks surrounding our call include: 1) Omicron’s impact being less severe and/or shorter than expected, 2) A material improvement in the company’s Take Rate (allowing Revenue to be less impacted by the potential GMV headwind), and/or 3) An accelerated acquisition of Active Riders.”

Related Articles

Lyft Added to Tactical Underperform List at Evercore ISI

Vaxxinity Shares Rise After First Patient Dosed in Parkinson's Study

Exclusive-Tereos to exit malt business, eyes Romanian sugar unit closure